Refacto (Antihemophilic Factor (Recombinant)) - Drug Interactions, Contraindications, Overdosage, etc

DRUG INTERACTIONS

REFACTO drug label information in our database does not contain a dedicated section on drug interactions. Please check subsections of WARNINGS AND PRECAUTIONS as well as other sources.

CONTRAINDICATIONS

Known hypersensitivity to mouse, hamster, or bovine proteins may be a contraindication to the use of ReFacto^® Antihemophilic Factor (Recombinant).

REFERENCES

1. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in hemophiliacs. Lancet. 1992;339:594-598.
2. Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood. 1994;83(9):2428-2435.
3. Lusher J, Arkin S, Abildgaard CF, Schwartz RS, Group TKPUPS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N Engl J Med. 1993;328:453-459.
4. Kessler C, Sachse K. Factor VIII:C inhibitor associated with monoclonal-antibody purified FVIII concentrate. Lancet 1990; 335:1403.
5. Scharrer I, Bray G. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Hemophilia 1999; 5:145.
6. Kessler CM. An Introduction to Factor VIII Inhibitors: The Detection and Quantitation. American Journal of Medicine 91 1991, (Supplement 5A): 1S-5S.

Wyeth^®

Wyeth Pharmaceuticals Inc.

Philadelphia, PA 19101

US Govt. License No. 3

Telephone: 1-800-934-5556

W10403C004 ET01 Rev 02/04